Reply  by Konstam, Marvin A. et al.
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fdvanced Heart Failure
nd Transplant Cardiology
s a Single Subspecialty May
estrict Access to Care
hile reading the Viewpoint by Konstam et al. (1), I was
ismayed to note that demonstration of competency in caring for
atients with severe heart failure is being tied to expertise in
ardiac transplantation. This linkage will effectively restrict ad-
anced heart failure care to the relatively few tertiary centers now
racticing transplantation, despite the fact that the overwhelming
ajority of patients with heart failure, including those with the
ost severe disease, are not candidates for transplantation. Fur-
hermore, transplant volume is static or declining while the disease
tself has become a major growing public health and economic
roblem. The majority of patients with heart failure, including
ost of the sickest, are cared for in a community setting. The
igration of maturing technologies for heart failure therapy to
ontransplanting community referral hospitals with demonstrated
xcellence in heart failure care may be hindered by this decision,
ffectively limiting therapeutic alternatives available to many sick
atients.
It is ironic that in 2004, Konstam (2) noted that “HF is unique
mong the subspecialties of cardiology, defined by the patient and
he disease, rather than by technical skill,” while the proposed heart
ailure competencies will be tied to rarely utilized procedures such
s endomyocardial biopsy and transplantation or “an expanding
rray of electrophysiologic. . .and complex percutaneous and sur-
ical procedures” (1). Both the 2004 and 2009 documents note the
mportance of disease management and suggest that the certified
pecialist should be “well-suited to provide guidance in the conduct
f disease management services” (2). Despite this, the clinical
roficiency list does not include any items related to disease
anagement.
Cardiac patients receive excellent care by subspecialists such as
lectrophysiologists and interventional cardiologists at a commu-
ity referral level throughout the country. Why should heart failure
e different? It would be unfortunate if a well-intended effort to
odify requirements for certifying competence in caring for ad-
anced heart failure resulted in limitation of care for the patients
ho need it the most. Rather than focusing on technical skills, the
oard emphasis should be on the knowledge tools requisite for
roviding superior care to patients at a local level without sending
hem to few and distant referral centers. As our heart failure
opulation grows, one can easily imagine those centers being
verwhelmed by the influx of heart failure patients in need of
onsultation and access to advanced care. Rather than creating
otential restrictions on access to care, we should be exploring how
o move advanced heart failure care into communities by cultivat-
ng and certifying heart failure care at a local level. iLee W. Jordan, MD
Heart Disease Management Clinic
iverside Methodist Hospital
535 Olentangy River Road
olumbus, Ohio 43214
-mail: lwjtn@earthlink.net
doi:10.1016/j.jacc.2009.03.075
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eply
e thank Dr. Jordan for his thoughtful remarks in response to our
ommentary (1). In our article, we describe the need for certifica-
ion of the secondary subspecialty of advanced heart failure and
ransplant cardiology and the competency requirements that have
een enumerated by the American Board of Internal Medicine
ABIM). In his letter, Dr. Jordan challenges the inclusion of
echnical competencies, including management of patients under-
oing cardiac transplant, and raises concerns that these require-
ents will preclude recognition of competency in heart failure
anagement within the community.
We wish to reaffirm the focus of the Heart Failure Society of
merica on the cognitive aspects of heart failure patient care and
lacement of the patient with heart failure at the center of all heart
ailure management competencies. We favor development of
pportunities for recognition of practice competencies in heart
ailure, short of ABIM secondary subspecialty certification and
ithout requirements for technical competencies. However, the
onsensus that evolved around the need for secondary subspecialty
ertification included the necessity of mastering the technical
spects of contemporary advanced heart failure management,
ncluding managing patients undergoing transplantation and ven-
ricular assist device placement. We and our colleagues across the
ardiology and internal medicine communities believe that com-
etencies in these areas represent key elements that set apart the
ubspecialist in advanced heart failure from the highly competent
ardiologists and internists who will continue to provide the vast
ajority of care to patients with heart failure.
We do not anticipate that the advanced heart failure and
ransplant cardiologist will limit his or her care to the transplant
enter. Many who gain these special competencies will practice
ithin the nontransplant center and community hospital setting.
he nature of the technical procedures offered to advanced heart
ailure patients will evolve in the coming years. As it does,
ncreasing numbers of patients undergoing these procedures will
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August 18, 2009:743–6eturn to the community and will require care from subspecialists
ith expertise in their management. The certified advanced heart
ailure and transplant cardiologist will have recognized expertise in
he full range of treatment options available to the patient with
dvanced heart failure and be fully qualified to care for patients
eceiving these treatments as they return to the community. We
elieve that recipients of certification in advanced heart failure and
ransplant cardiology, having demonstrated their competencies in
ll aspects of advanced heart failure management, will provide a
ital function both in the advanced heart failure center and within
he health care community at large.
Marvin A. Konstam, MD
ariell Jessup, MD
ary S. Francis, MD
ouglas L. Mann, MD
arry Greenberg, MD
Tufts Medical Center
he Cardiovascular Center
50 Washington Street
ox 108
oston, Massachusetts 02111-1526
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ost Would Fail to Benefit
rom JUPITER Intervention
he recent article by Michos and Blumenthal (1) estimates that
.5 million Americans are newly appropriate for statin therapy
ased on JUPITER (Justification for the Use of Statins in
rimary Prevention: an Intervention Trial Evaluating Rosuvas-
atin) study data. The authors fail to recognize, however, that
ost of these patients will die before they are likely to benefit.
As JUPITER reported an annual control event rate of 1.36%
or its primary end point, it would take 50.6 years for one-half
f the study population to benefit from the intervention. From
his value and published National Center for Health Statistics
ife expectancies, one can calculate from Table 1 the proportion
ikely to benefit at any given age.
Risk reduction is not beneficial if it does not prevent an
dverse outcome. Subjecting aging patients to an intervention
roportion Likely to Benefit FromUPITER Interventi n by Sex and Age
Table 1
Proportion Likely to Benefit From
JUPITER Intervention by Sex and Age
Age, Yrs
50 60 70 80 90
Men (%) 32 24 17 10 5trom which the overwhelming majority will not benefit is
linically inappropriate.
William M. Plonk, Jr, MD
Duke University Medical Center
edicine
ox 3003
urham, North Carolina 27710
-mail: bill.plonk@duke.edu
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eply
e thank Dr. Plonk for his letter regarding our recent publication
1). We agree that the incident rates for the primary end point in
he JUPITER (Justification for the Use of Statins in Primary
revention: an Intervention Trial Evaluating Rosuvastatin) trial
ere overall moderate in this primary prevention trial (0.77 and
.36 per 100 person-years of follow-up in the rosuvastatin and
lacebo groups, respectively) (2).
If we are interpreting Dr. Plonk’s analyses correctly, he applied
he 1.36% annual event rate found in the JUPITER placebo group
qually across age groups in his table, only accounting for de-
reased life expectancy with age. However, the risk of cardiovas-
ular events, many of which are nonfatal, also increases signifi-
antly with age (3). It appears that Dr. Plonk did not account for
he increasing risk for the events with age when he stratified by age
roups. Therefore, although the life expectancy is shorter at older
ges, the risk of cardiovascular events is greater, which means the
roportion that may benefit in the older age groups is likely greater
han his table suggests.
The median age in the JUPITER clinical trial was 66 years, and
he weighted median age group found in our NHANES (National
ealth and Nutrition Examination Survey) participants represen-
ative of the general U.S. population who met JUPITER eligibility
as similar at 67 years (interquartile range 57 to 75 years; median
ge of 60 years for men and 74 years for women). Therefore, even
hen Dr. Plonk’s estimates are used, a significant portion (20%
o 25%) of eligible 55- to 75-year-old patients would likely benefit
sing this JUPITER strategy.
Furthermore, in JUPITER trial, there are 5,500 patients 70
ears of age, and that subgroup had a highly significant 40%
eduction in the trial primary end point (95% confidence interval:
.45 to 0.82) with about a 2-year average follow-up time (Dr. Paul
. Ridker, personal communication, April 8, 2009). The purpose
f our analyses was simply to estimate the number of U.S. adults
ho would meet the JUPITER eligibility criteria. By increasing
ecades of age (50 to 59 years, 60 to 69 years, 70 to 79 years, 80
o 89 years), we estimate by using NHANES data that 29.4%,
7.8%, 28.1%, and 14.7% respectively, would meet JUPITER
ligibility criteria. Certainly the decision whether to initiate statin
herapy should be made on a patient-specific basis, and statinWomen (%) 36 28 19 12 6
herapy may not be indicated in those patients who are unlikely to
